PDGFRA and anaplastic oligodendroglioma: Taken individually, we observed PDGFRA amplification in 56/236 (23.7%) cases (6/37, 16.2% anaplastic oligodendroglioma; 2/11, 18.1% anaplastic astrocytoma; 48/188, 25.5% glioblastoma); KIT amplification in 49/235 (20.9%) cases (4/30, 13.3% anaplastic oligodendroglioma; 3/11, 27.3% anaplastic astrocytoma; 42/194, 21.6% glioblastoma); and VEGFR2 amplification in 26/190 (13.7%) cases (2/27, 7.4% anaplastic oligodendroglioma; 1/9, 11.1% anaplastic astrocytoma; 23/154, 14.9% glioblastoma).